PF-5212374

PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913) . PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases[1].

Product Specifications

CAS Number

[1169717-01-4]

Product Name Alternative

TRU-015

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pf-5212374-tru-015.html

Purity

97.9

Smiles

[PF-5212374]

References & Citations

[1]Hayden-Ledbetter MS, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res. 2009 Apr 15;15 (8) :2739-46.